Refine
Has Fulltext
- yes (85)
Is part of the Bibliography
- yes (85)
Year of publication
Document Type
- Journal article (82)
- Report (2)
- Review (1)
Language
- English (85)
Keywords
- Neurobiologie (41)
- Medizin (10)
- Durchblutung (5)
- Gehirn (5)
- rats (5)
- active zone (4)
- traumatic brain injury (4)
- Hypothalamus (3)
- Prostaglandine (3)
- TRH (3)
- blood pressure (3)
- closed head injury (3)
- Lipopolysaccharide (2)
- Mesenteric circulation (2)
- Mice (2)
- Neurophysiologie (2)
- Physiologie (2)
- Stroke (2)
- blastocysts (2)
- brain development (2)
- cardiac output (2)
- contact-kinin system (2)
- factor XII (2)
- heart rate (2)
- inflammation (2)
- lines (2)
- mice (2)
- tumor necrosis factor (2)
- 2-photon microscopy (1)
- Anaphylactic shock (1)
- Anaphylaxis (1)
- Autoradiography (1)
- Axonal degeneration (1)
- BN 52021 (1)
- Biowissenschaften (1)
- Blutdruck (1)
- Brain stem (1)
- Bruchpilot (1)
- C1-inhibitor (1)
- CA2+ channels (1)
- CA3 (1)
- CA3 pyrimidal cells (1)
- CNS cancer (1)
- Cardiovascular (1)
- Cardiovascular system (1)
- Cerebral-ischemia (1)
- Cranial window (1)
- Crespi effect (1)
- Cryolesion (1)
- Drosophila melanogaster (1)
- ED2 (1)
- Endothelial cell (1)
- Endothelium (1)
- Endothelzelle (1)
- Experimental brain trauma (1)
- Fluorescence (1)
- Focal brain ischemia (1)
- HLA-G gene (1)
- Head-injury (1)
- Hemodynamic depression (1)
- Hemorrhage (1)
- Hypertension (1)
- IBA-1 (1)
- Icosanoid (1)
- In vivo imaging (1)
- In-vivo dia lysis (1)
- IntelliCage (1)
- Intercellular adhesion molecule 1 (1)
- Intravascular coagulation (1)
- Lipoxin (1)
- Locus coeruleus (1)
- Microinjection (1)
- Model (1)
- Molecular-weight heparin (1)
- Monocyte (1)
- Mouse model (1)
- N-Acetyl-leukotriene E4 (1)
- Neurons (1)
- Neuropeptides (1)
- PAF-acether (1)
- PET (1)
- PFA in ethanol (1)
- Peptide-leukotrienes (1)
- Prostaglandins (1)
- R-715 (1)
- RIM-binding protein (1)
- RIM1α (1)
- Rat hippocampus (1)
- Rats (1)
- Renal circulation (1)
- Reperfusion (1)
- SV pool (1)
- Secondary traumatic brain damage (1)
- Silver degeneration staining (1)
- Supraoptic nucleus (1)
- Sympathetic nervous system (1)
- T lymphocytes (1)
- T-2 toxin (1)
- TBI (1)
- TNF-α (1)
- TSPO (1)
- Thromboplastin (1)
- Thrombus formation (1)
- Thyreotropin-Releasinghormon (1)
- Trauma (1)
- Vasopressin (1)
- Ventilation (1)
- Von Willebrand factor (1)
- Willebrand-Faktor (1)
- Zell-Adhäsionsmolekül (1)
- [3H][3Me-His2]-TRH (1)
- acute brain slices (1)
- anxiety (1)
- astrocyte (1)
- astrocytes (1)
- autoradiography (1)
- benzodiazepine antagonist. (1)
- blood-brain barrier (1)
- bradykinin (1)
- brain (1)
- brain edema (1)
- cancer (1)
- catecholamlnes (1)
- cerebraI ischemia (1)
- cerebral blood flow (1)
- cerebral ischemia (1)
- chlorisondamine (1)
- chronic heart failure (1)
- compaction (1)
- cytokines (1)
- dSTORM (1)
- damage control orthopedics (1)
- dennorphin (1)
- depression (1)
- derivation (1)
- dermorphin (1)
- differentiation (1)
- diffuse (1)
- edema (1)
- electron tomography (1)
- femoral fracture (1)
- flumazenil (1)
- focal (1)
- focal brain lesion (1)
- hemorrhagic shock (1)
- high-pressure freezing (1)
- high-pressure freezing/freeze substitution (1)
- hippocampal (1)
- hippocampal mossy fiber bouton (1)
- homeostasis (1)
- hypovolemic hypotension (1)
- immune response (1)
- immunofluorescence (1)
- immunohistochemistry (1)
- in vitro (1)
- in-vitro (1)
- in-vivo (1)
- kallikrein–kinin system (1)
- kinin receptor (1)
- kinin receptors (1)
- lipopolysaccharides (1)
- lnflammation (1)
- locus coeruleus (1)
- metabolism (1)
- methylation (1)
- mhc molecules (1)
- microglia (1)
- mortality (1)
- mossy fiber synapses (1)
- mycotoxin (1)
- myocardial infarction (1)
- naloxonazine (1)
- naloxone (1)
- nanotopology (1)
- nervous system (1)
- neurobehavioural deficits (1)
- neuroinflammation (1)
- neuromuscular junction (1)
- neuronal damage (1)
- neurons (1)
- neuroprotection (1)
- object recognition memory (1)
- opiates (1)
- opioid peptides (1)
- opioid receptors (1)
- opioid-benzodiazepine interactions (1)
- paediatric cancer (1)
- plasticity (1)
- platelet activating factor (1)
- platelet-activating factor (1)
- platform (1)
- pluripotent (1)
- presynaptic (1)
- presynaptic plasticity (1)
- prostacyclins (1)
- proteins (1)
- rat (1)
- regional blood flow (1)
- regional blood ftow (1)
- release (1)
- renin (1)
- reperfusion (1)
- respiration (1)
- reveals (1)
- shock (1)
- specification (1)
- stem/progenitor cells (1)
- stress (1)
- subarachnoid hemorrhage (SAH) (1)
- super-resolution microscopy (1)
- sympathetic nerve activity. (1)
- synaptic ultrastructure (1)
- therapy (1)
- thromboinflammation (1)
- thrombosis (1)
- total peripheral resistance (1)
- vasopressin (1)
- von Willebrand factor (1)
- weight drop (1)
- µ opioid receptors (1)
- µ·Opioid receptor subtypes (1)
- β-APP (1)
Institute
- Neurochirurgische Klinik und Poliklinik (80)
- Neurologische Klinik und Poliklinik (9)
- Physiologisches Institut (9)
- Klinik und Poliklinik für Unfall-, Hand-, Plastische und Wiederherstellungschirurgie (Chirurgische Klinik II) (4)
- Center for Computational and Theoretical Biology (3)
- Theodor-Boveri-Institut für Biowissenschaften (3)
- Institut für Medizinische Strahlenkunde und Zellforschung (2)
- Kinderklinik und Poliklinik (2)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (2)
- Rudolf-Virchow-Zentrum (2)
The endogenous opioid system includes three major families of peptides [22): dynorphins (derived from pre-proenkephalin B); endorphins (derived from pre-proopiomelanocortin) and enkephalins (derived from pre-proenkephalin A). Multiple species of opioid peptides are derived from these major precursors and many of them possess potent cardiovascular properties. Multiple forms of opioid receptors have been defined in the central nervous system. Although the relationship of these receptors to the multiple actions of the opioid systems is not weil understood, some predications can be made: in vitro the dynorphin-related peptidesbind preferentially to kappa-opioid receptors; the enkephalins bind preferentially to delta and JL-opioid receptors and while beta-endorphin binds to mu- and delta-, but not to kappa-opioid receptors. While littleis known on the roJe ofthe opioid system in normal cardiovascular regulation, it has become clear that cardiovascular stress situations substantially modify the activity ofthe endogenous opioid system. This review focuses on the mu-opioid system in the hypothalamus with special emphasis on its potential roJe in cardiovascular control of both normal and pathophysiologic states.
Stroke risk factors prepare rat brainstem tissues for a modified localized Shwartzman reaction
(1988)
Stroke risk factors such as hypertension, diabetes, advanced age, and genetic predisposition to stroke were demonstrated to prepare rat brainstem tissues for a modified local Shwartzman reaction. A single intracisternal injection of endotoxin provoked the reaction, and affected rats manifested neurologie deficits accompanied by pathologie lesions. Brainstem infarcts developed in only a small proportion of rats without recognized risk factors after intracisternal injection of endotoxin. Thus, stroke risk factors, whieh are ordinarily regarded as operating through acceleration of atherosclerosis, may predispose to brain ischemia by local effects on brain mierocirculation such as those thought to underlie preparation of a tissue for the local Shwartzman reaction.
Trichothecenes are mycotoxins which produce Iethai toxicosis in humans and animals, yet no adequate therapeutic regimen has been developed. This study provides evidence that the selective platelet activating factor (PAF) antagonist, BN 52021 (5-15 mg/kg i.v.) can prolong the survival of conscious rats exposed to a highly Iethai T -2 toxicosis. These data also suggest that P AF is an important mediator of this unique toxicosis.
This review is an attempt to highlight evidence that may implicate the endogenaus opioid system in the pathogenesis of hypertension in humans. The evidence raised includes biochemical, physiological, pharmacological, and behavioral studies con~ucted in in vitro andin vivo systems, experimental models of hypertension, and hornans with essential hypertension. While the compelling biochemical and pharmacological evidence in experimental animals clearly shows the presence of opioid peptides and their receptors in strategic sites of cardiovascular control and potent cardiovascular response to opioid peptides, opioid antagonists show no consistent blockade or reversal of hypertension in experimental animals or humans. One possible explanation for this phenomenon could be the vast redundancy in systems regulating blood pressure (i.e., the blockade ofone system stillleaves many other systerils fully able to rapidly offset the eliminated system). Regarding the opioid system, the situation is much more complex, since some opioid receptors (\(\mu\)-type) niediate pressor responses, while other receptors (\(\kappa\)type) mediate depressor responses. Therefore, nonselective opioid receptor antagonists (e.g., naloxone), which block both types ofreceptors, can be devoid ofany cardiovascular activity, while a selective \(\mu\)-receptor antagonist or a selective arid potent \(\kappa\)-receptor agonist may produce the desired antihypertensive elfect. A combination of both actions (i.e., a drug that is both \(\mu\)antagonist and a \(\kappa\)antagonist) might be even more advantageous. Until such compounds are developed, this hypothesis will be hard to prove.
The endogenous opioid system includes three major families of peptides: dynorphins (derived from pre-proenkephalin B), endorphins (derived from pre-proopiomelanocortin), and enkephalins (derived from pre-proenkephalin A). Multiple species of opioid peptides are derived from these major precursors and many of them possess potent cardiovascular properties. Opioid peptides and opioid receptors, of which multiple forms have been defined, are present in the central nervous system and peripheral neural elements. In the central nervous system, opioid peptides and receptors are found in forebrain and hindbrain nuclei involved in baroregulation, sympathoadrenal activation, and several other vital autonomic functions. In the periphery, opioid peptides are found in autonomic ganglia, adrenal gland, heart, and other organs; multiple opioid receptors are also found in vascular tissue, heart, and kidneys. Although little is known to date on the regulatory mechanisms of the opioid system in normal cardiovascular states, it became clear that cardiovascular stress situations substantially modify the activity of the endogenous opioid system. The purpose of this review is to clarify the sites of interaction of the opioid system with all major components of the cardiovascular system and indicate the potential role of this system in the ontogenesis of cardiac malfunction, vascular diseases, and hypertension.
Enkephalins and their receptors are found in neurons and nerve terminals known to be involved in central cardiovascular control as well as the peripheral sympathetic and parasympathetic systems. Enkephalins and opioid receptors were also iden tified in the heart, kidneys, and blood vessels. The enkephalins interact with several specific receptors, of which p, 0, and K have been best characterized. Enkephalins administered to humans or animals produce cardiovascular effects which depend on the spedes, route of administration, anesthesia, and the selectivity for receptor subtype. While little information exists on the role of enkephalins in normal cardiovascular control, current data suggest that enkephalins might have a role in cardiovascular stress responses such os in shock and trauma.
Thyrotropin releasing hormone (TRH, I-pyroglutamyl-l-histidyl-l-prolinamide) was the fIrst hypothalamic releasing SUbstance to be isolated, chemically characterized and synthetized /1/. The studies to date have revealed that the thyrotropin release from the pituitary gland is only one of the numerous actions of TRH. In addition to its endocrine actions (TSH and prolactin release) this tripeptide has central nervous system actions totally unrelated to its effects on the hypothalamo-pituitary axis. This review aims to summarize the studies on the central nervous system' actions of TRH with special emphasis on the autonomic pharmacology of this peptide.
Thyrotropin releasing hormone (TRH), 10 pmol kg-1 injected in the region of locus coeruleus, caused a rapid (within 1 min) rise of mean arterial pressure in the urethane- naesthetized rat. No clear-cut effects in heart rate or ventilation were observed. When TRH was injected into the lateral ventricle, a dose more than 10-fold higher was required to achieve a comparable rise in arterial pressure. It is concluded that TRH may have a physiological rote in centrat cardiovascular regulation.
Cardioventilator responses were studied in anaesthetized rats after injections of TRH into either the lateral (i.c.v. lat) or the fourth (i.c.v. IV) cerebral ventricles. TRH induced a morerapid hypertensive effect i.c.v. IV than i.c.v. lat. Blocking of the cerebral aqueduct abolished the hypertensive and tachypnoeic effects of TRH i.c.v. lat but not those of TRH i.c.v. IV. It is concluded that TRH increased blood pressure and ventilation rate via brain stem structures close to the fourtli ventricle.
ln the present study the effects of thyrotropin releasing hormone (TRH) and its stable analogue, CG3703, on cardiac output (thermodilution, Cardiomax) and regional blood flow (BF; directional pulsed Doppler technique) were investigated in hypovolemic hypotension in the rat. In urethan-anesthetized rats TRH (0.5 or 2 mg/ kg ia) or CG3703 (0.05 or 0.5 mg/kg ia) reversed the bleeding (27% of the blood volume)-induced decreases in mean arterial ...
The acute effect ofT-2 toxemia on local blood flow and vascular resistance in hindquarter. mesenteric. and renal vascular beds was continuously measured by the directional pulsed Doppler technique in conscious, male Sprague-Dawley rats. Intravenous injection ofT-2 toxin (I mg/kg) in the conscious rat reduced blood flow and increased vascular resistance in all blood vessels studied but had no significant effect on mean arterial pressure or heart rate. The blood flow in hindquarters gradually decreased to a minimum of -77 ± 9% (mean ±SE) 6 hr after the toxin injection. The hindquarter vascular resistance concomitantly increased to a maximum value of + 323 ± 69% above thc resistance before toxin administration. Mesenteric and renal blood flow initially increased (slightly) and then gradually decreased. The maximum drop of blood flow, -90 ± 13% and -76 ± 13% for the mesenteric and renal vascular beds, respectively, was achieved 4 hr after T-2 toxin injection and the blood flow values remained low for up to 6 hr. Simultaneously with the impairment of
The cardiovascular and endocrine activity of three analogs of thyrotropin releasing hor.mone (TRH), 4-nitro-imidazole TRH (4-nitroTRH), 2-trifluoro-methyl-imidazole TRH (2-TFM-TRH) and 4-trifluoromethyl- imidazole TRH (4-TFM-TRH), was compared to TRH in conscious rats. Injection of TRH or the three analogs (1 mg/kg or 5 mg/kg) into the arterial line induced increases in mean arterial pressure, pulse pressure and heart rate and raised plasma prolactin (PRL). None of the analogs were more potent than TRH in inducing cardiovascular changes. The 4-TFM-TRH was significantly less potent than the 2-TFM-TRH in increasing blood pressure, while the nitro-TRH was more potent than the 2-TFM-TRH in producing tachycardia. TRH induced a two-fold increase in PRL at the 5 mg/kg dose, while both the fluorinated analogs elici ted a 4 to 5 fold increase in PRL at the higher dose. The present results suggest that the receptors for TRH-elicited PRL release differ from TRH-receptors involved in its cardiovascular actions.
The endogenous opioid system has been reported to depress the cardiovascular system during shock states, since naloxone, a potent opiate antagonist, enhances recovery of hemodynamic variables in various shock states. However, the effect of naloxone on long-term survival of experimental animals exposed to hypovolemic hypotension is not clear. The present studies tested the capacity of various doses of naloxone to protect conscious rats from mortality following various bleeding paradigms. In addition, the effect of morphine on survival of rats exposed to hemorrhage was also examined. In the six different experimental protocols tested, naloxone treatments failed to improve short- or long-term survival; in fact, naloxone treatment reduced short-term survival in two of the experimental protocols. Morphine injection, however, enhanced the mortality of rats exposed to hemorrhage in a dose-dependent manner. It is concluded that while opiates administered exogenously decrease survival after acute bleeding, naloxone has no protective action in such states and, like morphine, it may decrease survival in some situations.
Thromboxanes are abundantly present in the rat brain but their possible physiological functions in the brain are not known. The prostaglandin endoperoxide analogue U-46619 is a selective agonist of TxA2 receptors in many peripheral tissues. In the present study the ·central cardiovascular and ventilatory effects of U-46619 were investigated in rats. In conscious spontaneously hypertensive rats (SHR) U-46619 (1-100 nmol/kg i.c.v.) induced a strong dose-related increase in blood pressure but had no significant effect on heart rate. In conscious normotensive rats (NR) neither blood pressure nor heart rate was significantly affected. Furthermore, U-46619 (0.1-100 nmol/kg i.c.v.) had no significant effect on blood pressure, heart rate or ventilation in urethane-anaesthetised NR . The results demonstrate an increased sensitivity of SHR to TxA2.
In addition to the endocrine effects, the thyrotropin releasing hormone (TRH) is known to induce dose-dependent increases in blood pressure and heart rate after intracerebroventricular (i.c.v.) administration in urethane-anaesthetised rats (1, 2). The a~ of the present study was to investigate whether TRH has similar effects in conscious rats of various strains i.e. spontaneously hypertensive rats (SHR), normotensive Wistar-Kyoto (WKY) and Wistar (NR) rats.
Prostag1andin F\(_{2\alpha}\) (PGF\(_{2\alpha}\)) is one of the most common metabo1ites of arachidonic acid (M) in rat brain. When administered intracerebroventricularly (i.c.v.) to rats, both AA and PGFal exert dose-related hypertensive, tachycardic and hyperthermic effects. Metabolie alterations in the endogenaus formation of some prostaglandins in the brain-stem of spontaneously hypertensive rats (SHR) have been reported. Therefore the central effects of AA and PGF \(_{2\alpha}\) on blood pressure, heart rate and body temperature were studied both in SHR and nonootensive Wistar rats (NR) under urethane-anaesthesia. The hypertensive effect of AA i.c.v. (0.01-100 \(\mu\)g/rat) was larger in magni tude in SHR than in NR, but there was no significant difference in the M-induced changes of heart rate and body temperature between the groups. Pretreatment of NR wi th soditm1 :meclofenamate (1 mg/rat i.c.v.) antagonised the central effects of M indicating that these effects are not due to M itself but to its conversion to prostaglandins. Unlike the effects of AA, the central hypertensive, tachycardic and hyperthennic responses to PGF\(_{2\alpha}\) (0.5-50 l-lg/rat i.c.v .) were significantly attenuated in SHR. The present results obtained with M are conpatible with the previous assumption that the synthesis of prostaglandins in the brain of SHR might differ from that in NR. The results also demonstrate that the central effects of PGF\(_{2\alpha}\) are reduced in SHR.